Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant

临床前开发一种核靶向生物制剂，可安全地增加干细胞体内扩增，以加速化疗和骨髓移植后中性粒细胞减少症的恢复

• 批准号: 10685290
• 负责人: Jeremy A Elser
• 金额: $ 23.03万
• 依托单位: SHIP OF THESEUS, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-17 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10685290
• 关键词: ANXA5 gene; Acceleration; Adverse effects; Adverse event; Aftercare; Apoptosis; Apoptotic; Biological; Biological Assay; Blood; Bone Marrow; Bone Marrow Diseases; Bone Marrow Transplantation; CD34 gene; Cell Nucleus; Cell Transplantation; Cells; Chemotherapy and/or radiation; Chimeric Proteins; Chimerism; Clinic; Clinical; Clinical Trials; Complex; Consumption; Data; Disease; Dose; Dyes; Engraftment; Excision; Exploratory/Developmental Grants Phase II; Exposure to; Female; Fluorescence Microscopy; Future; Gel; Genetic; Goals; Half-Life; Hela Cells; Hematopoietic; Hematopoietic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Homeodomain Proteins; Hospitalization; Hour; Human; Immune system; Immunodeficient Mouse; In Vitro; Infection; Inflammatory; Inpatients; Intravenous infusion procedures; Lead; Legal patent; Libraries; Life; Malignant Bone Marrow Neoplasm; Measures; Methodology; Methods; Modeling; Monitor; Mucositis; Mus; Myelogenous; Myeloproliferative disease; Necrosis; Neutropenia; Nuclear; Patient-Focused Outcomes; Patients; Penetration; Peptides; Pharmaceutical Preparations; Phase; Predisposition; Proliferating; Proteins; Recovery; Resistance; Risk; Safety; Scanning; Site; Source; Stains; System; Therapeutic; Time; Toxic effect; Toxicology; Transplant Recipients; Transplantation; Transplantation Conditioning; candidate identification; candidate selection; chemotherapy; clinical investigation; comparison control; conditioning; cost; cytotoxicity; efficacy evaluation; efficacy study; experience; hematopoietic stem cell expansion; high risk; improved; in vivo; infection risk; innovation; lead candidate; male; man; manufacture; mutant; novel; overexpression; peripheral blood; post-transplant; pre-clinical; preclinical development; reconstitution; safety study; screening; stem cell expansion; stem cell function; transcription factor; uptake

Hematopoietic stem cell (HSC) transplants (HSCTs) are considered a potentially curative option for patients with certain cancers of the blood and bone marrow and over 20,000 HSCTs are performed in the US each year. However, HSCTs are associated with high risk due to the required removal of diseased bone marrow before transplantation. Until the transplanted cells engraft and proliferate enough to reconstitute the patient’s immune system, the patient is considered neutropenic during which they are highly susceptible to infection. In addition to the potentially life-threatening physical risk to the patient, neutropenia necessitates long hospitalization time that can in part drives the expensive cost of HSCTs ranging up to $400,000 in the US. A current strategy in clinical trials is to transplant larger pools of donor HSCs to shorten the neutropenic phase. However, these approaches all rely on ex vivo culturing of donor cells that depend on imperfect man-made culture systems that may disrupt the proper function of the stem cells and can be prohibitively expensive. Ship of Theseus’ innovative solution is a drug that will be used for a brief, one-time exposure to donor cells prior to transplantation that improves expansion in vivo. Our drug is a patented mutant of nuclear transcription factor, Homeobox protein B4 (HOXB4(m)), which promotes HSC expansion without differentiation. HOXB4(m) has improved degradation resistance, which enables us to overcome several shortcomings of HOXB4 (e.g., short protein half-life and myeloproliferative disorders associated with genetic overexpression). By elongating its intracellular half-life, HOXB4(m) is practical for clinical use while potentially avoiding adverse effects induced by constitutive overexpression. Early preclinical data indicating treating cells with HOXB4(m) can expand all major lineages of HSCs while maintaining multipotency. However, current delivery of HOXB4(m) is limited by its ability to penetrate cells and localize in the nucleus, the site of its bioactivity. The goal of this R61/R33 proposal is to improve efficiency and safety of HOXB4(m) by improving its nuclear delivery. This will be accomplished through the execution of 3 aims. In Aim 1 (R61), we will perform a library screen to identify optimal combinations of cell penetrating peptide and nuclear targeting motifs for HOXB4(m) nuclear localization. In Aim 2 (R33), we will assess in vitro efficacy of the top candidates to select a lead candidate. In Aim 3 (R33), we will demonstrate long-term hematopoietic reconstitution without adverse effects or GVHD of our lead candidate in vivo in a mouse HSCT study. Successful completion of this R61/R33 program will demonstrate feasibility of an improved HOXB4(m) candidate that maintains efficacy at lower concentrations and briefer exposure periods. This project will provide the necessary data to support future extensive in vivo efficacy and safety studies necessary for an IND submission. With HOXB4(m), we can circumvent the original hurdles of HOXB4 and improve expansion in vivo to benefit HSCT patients by shortening the neutropenic phase to reduce infection, hospitalization time, and cost.

造血干细胞（HSC）移植（HSCTs）被认为是一种潜在的治疗选择